Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements - Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval - Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...